BCL2 and cancer: Ligand binding to TAM family receptors activates downstream signaling pathways critical for cancer, including the JAK-STAT, MAPK-ERK, and PI3K-AKT-mTOR pathways and pro-survival pathways involving BCL-2 and SURVIVIN [10,11].